Hims & Hers Health (HIMS) is trading at $20.01, below every listed short- and medium-term moving average, while analyst actions on November 10, 2026 were mixed to negative, with four firms trimming...

Hims & Hers Health (HIMS) closed at $20.01, up 2.51% on the day, but the larger structure remains damaged. The stock is trading under its 7-day SMA of $22.75, its 20-day SMA of $25.67, and its 50-day SMA of $27.78, which keeps the moving-average stack firmly bearish. The current price is also sitting just above the Bollinger lower band at $19.71, so the market is testing a lower-volatility support zone rather than breaking out of one.

That matters because the tape is still discounting the prior trend, not confirming a reversal. HIMS’s 24-hour range of $19.08 to $20.90 shows the stock is still trying to stabilize around the $20 pivot, but the move has not yet reclaimed nearby resistance.

The latest analyst changes were mostly cuts. Craig Hettenbach at Morgan Stanley kept an Equal-Weight rating and lowered the target to $25 from $28. Ryan MacDonald at Needham kept a Buy rating but cut the target to $32 from $42. Mark Mahaney at Evercore ISI kept an In-Line rating and raised the target to $27 from $24. Jefferies maintained a Hold rating and reduced its target to $24 from $31.

The useful takeaway is not that targets cluster around one exact level, but that the post-earnings read-through was cautious. The range now runs from $24 to $32, which still leaves room above spot, but the direction of travel in the revisions was mostly lower.

Source link